Genetically predicted liability to Sjögren’s syndrome substantially increases the risk of developing several subtypes of B-cell non-Hodgkin lymphoma, with the entire shared genetic effect concentrated in the human major histocompatibility complex region on chromosome 6. In a comprehensive investigation integrating post-genome-wide association study causal inference, high-resolution human leukocyte antigen imputation, single-cell transcriptomics of affected salivary tissue, and targeted cellular perturbation experiments, investigators evaluated the mechanisms that translate autoimmune inflammation into neoplastic B-cell proliferation. The findings demonstrate that inherited variation within the classical 8.1 ancestral haplotype confers a shared predisposition to both autoimmune exocrine disease and subsequent lymphomagenesis. Rather than operating through a diffuse genome-wide polygenic architecture, the disease interface converges within the salivary tissue microenvironment onto infiltrating B cells, where the invariant chain and innate cytokine receptor CD74 serves as an essential regulatory conduit transducing macrophage migration inhibitory factor signals into intracellular survival pathways.
Sjögren’s syndrome has long been recognized clinically as an autoimmune disorder marked by chronic lymphocytic infiltration of the salivary and lacrimal glands, accompanied by a relative risk of non-Hodgkin lymphoma that exceeds that observed in any other systemic autoimmune disorder. The malignant transformations arising in this setting are predominantly B-cell histologies, most frequently presenting as marginal-zone or mucosa-associated lymphoid tissue lymphomas within the affected salivary glands. While earlier observational cohort investigations identified clinical warning signs of neoplastic progression, including persistent salivary gland enlargement, cryoglobulinemia, and ectopic germinal-center-like lymphoid structures, observational studies could not disentangle whether these markers represented shared primary etiology or confounding secondary to chronic inflammation, systemic disease severity, and cumulative immunosuppressive therapy. By leveraging genomic methods, the research team sought to determine whether direct germline causal variation accounts for the transition from benign autoimmune infiltration to frank lymphomatous transformation.
To evaluate polygenic overlap across conditions, the investigators examined genome-wide summary statistics from FinnGen release R13 spanning Sjögren’s syndrome alongside eight distinct lymphoma phenotypes, incorporating marginal-zone, diffuse large B-cell, follicular, chronic lymphocytic leukemia, mantle-cell, T-cell, and Hodgkin lymphomas, alongside autoimmune comparators such as rheumatoid arthritis. Cross-trait linkage disequilibrium score regression revealed positive genetic correlations between Sjögren’s syndrome and the lymphoma subtypes, such as an estimated correlation of 0.25 with marginal-zone lymphoma, yet these genome-wide correlations did not achieve formal statistical significance due to the limited statistical power inherent in existing lymphoma cohorts. Consequently, the team implemented two-sample bidirectional Mendelian randomization to test for directional causal relationships using genome-wide significant genetic variants pruned by genomic position within independent five-hundred-kilobase windows across the genome without relying on an external linkage reference panel.
The Mendelian randomization analyses established a clear, directional causal effect of genetically predicted Sjögren’s syndrome on lymphoma risk. An increase of one standard deviation in genetic liability to Sjögren’s syndrome conferred an odds ratio of 1.82 for marginal-zone lymphoma, an odds ratio of 1.42 for diffuse large B-cell lymphoma, and an odds ratio of 1.30 for overall non-Hodgkin lymphoma. Steiger filtering verified the directional validity of each instrument, confirming that the genetic variants influenced lymphoma via Sjögren’s liability rather than operating in reverse. Crucially, when the researchers excluded the major histocompatibility complex locus, defined as chromosome 6 from 25 to 35 megabases, every headline association attenuated to the null. The odds ratio for marginal-zone lymphoma dropped to 1.36 with confidence intervals encompassing unity, while the effect on diffuse large B-cell lymphoma diminished entirely to 1.00, demonstrating that the shared liability is governed strictly by major histocompatibility complex architecture.
Subsequent Bayesian colocalization supported this localized genetic architecture, confirming that the primary Sjögren’s syndrome association and the marginal-zone lymphoma signal shared a single underlying causal variant, yielding a posterior probability of 0.94 in an independent marginal-zone lymphoma cohort, which was also replicated in independent diffuse large B-cell lymphoma cohorts. To pinpoint the specific alleles responsible, the investigators applied summary-based human leukocyte antigen imputation using the multi-ancestry HLA-TAPAS reference panel spanning chromosome 6 from 28 to 34 megabases. This resolved the shared locus directly to the six canonical components of the ancestral 8.1 haplotype, namely HLA-A*01, HLA-C*07, HLA-B*08, HLA-DRB1*03, HLA-DQA1*05, and HLA-DQB1*02. Every component of this ancestral haplotype associated in an identical risk direction across Sjögren’s syndrome and the examined lymphoma subtypes, led by powerful signals at HLA-B*08 and HLA-DRB1*03, whereas non-haplotype alleles exhibited discordant or protective associations.
Refining the locus further through amino-acid fine-mapping revealed that the class II signal mapped specifically to peptide-binding groove residues at positions 71, 74, and 77 of HLA-DRB1, alongside position 9 within the class I molecule HLA-B. To determine which cell types harbor this shared genetic liability, the investigators analyzed single-cell RNA-sequencing data comprising 42,288 cells isolated from human salivary glands, integrated using deep generative modeling. Single-cell disease relevance score profiling revealed that Sjögren’s syndrome genetic risk was most heavily concentrated in salivary B cells. When major histocompatibility complex genes were computationally omitted from the gene scoring set, this enrichment collapsed dramatically, mirroring the loss of causal signal observed in the regional Mendelian randomization knockout and demonstrating that salivary B cells represent the primary cellular compartment carrying the inherited risk.
Cellular communication networks constructed using single-cell transcriptomics demonstrated that the salivary tissue microenvironment undergoes profound reorganization during disease progression. By contrasting seven primary Sjögren’s syndrome salivary gland samples with six non-autoimmune sicca control specimens across 104 sample-by-cell-type measurements, the investigators observed an expansion of infiltrating lymphoid populations. Descriptively, primary disease tissues showed higher mean proportions of B cells with a log2 ratio of 3.56, plasma cells with 1.52, CD8-positive T cells with 1.39, and CD4-positive T cells with 1.22, alongside corresponding reductions in stromal fibroblasts, endothelial cells, and resident macrophages. Within this remodeled inflammatory landscape, cell-cell interaction modeling identified macrophage migration inhibitory factor as the predominant communication cascade terminating on B cells. Plasma cells represented the primary source of this factor, while B cells expressed the highest levels of its receptor complex.
Transcriptional profiling showed that the ligand-binding receptor CD74, which functions natively as the invariant chain facilitating major histocompatibility class II assembly, is prominently expressed on salivary B cells, where it acts as an innate cytokine sensor alongside co-receptors CXCR4 and CD44. Notably, the genes encoding the pathway itself—including CD74, MIF, CXCR4, and CD44—showed only nominal associations in discovery genome-wide association statistics without reaching genome-wide significance. This genetic dissociation indicates that the pathway operates not as an independent genetic initiator, but rather as an innate molecular effector network that is constitutively engaged by expanded inflammatory cell populations. Constructing a cross-disease pseudotime trajectory spanning salivary B cells and splenic marginal-zone lymphoma B cells revealed a continuous upregulation of the class II transcriptional module along the disease axis, with neoplastic cells exhibiting peak expression.
To establish functional causality, the authors perturbed the pathway in cultured human Raji B-lymphoma cells across seven distinct experimental conditions. Exposure to interferon-gamma established an inflamed, disease-relevant baseline, dramatically inducing transcripts and protein levels of CD74, CIITA, and HLA-DR. Subsequent administration of recombinant macrophage migration inhibitory factor triggered robust downstream activation of phosphorylated AKT, phosphorylated p65 of the nuclear factor kappa-B pathway, and the anti-apoptotic effector BCL-xL, leading to measurable gains in cell viability. Conversely, blocking the cytokine using the small-molecule inhibitor ISO-1 or silencing CD74 expression via small interfering RNA abolished this survival signaling and triggered marked increases in apoptotic cleaved PARP. Introducing the chemical AKT activator SC79 restored downstream phosphorylation and cellular viability despite ongoing CD74 knockdown, conclusively positioning AKT activation downstream of the CD74-dependent cytokine signal.
Finally, the clinical and prognostic relevance of this survival circuit was validated in an independent public gene-expression cohort of 107 patients with chronic lymphocytic leukemia, an indolent mature B-cell neoplasm linked to Sjögren’s syndrome. Patients presenting with elevated CD74 expression experienced significantly shorter overall survival, reflected by a continuous hazard ratio of 2.08 per standard-deviation increment, and a median-split hazard ratio of 2.14. High receptor expression similarly predicted a markedly accelerated time-to-first-treatment, exhibiting a hazard ratio of 3.14. Prognostic risk stratified progressively across expression tertiles, and the adverse survival signal was specific to the ligand-receptor pair of MIF and CD74 rather than the co-receptors CXCR4 and CD44, confirming the translational relevance of the axis in malignant B-cell disorders.
The study authors emphasized several methodological and biological limitations bounding these conclusions. The initial lymphoma genome-wide association datasets were underpowered to establish genome-wide polygenic correlations and were derived almost exclusively from cohorts of European ancestry, underscoring the need for confirmation across more diverse populations. Furthermore, classical human leukocyte antigen alleles were imputed from dense single-nucleotide polymorphism data rather than directly sequenced, and the cross-disease single-cell trajectory linked salivary specimens and splenic lymphoma cells derived from distinct patient datasets. The in vitro mechanistic perturbations were conducted in a single continuous cell line, which cannot reproduce complete in vivo lymphomagenesis. Consequently, prospective validation in tissue-matched cohorts will be essential before CD74 and its associated signaling network can be translated into clinical risk stratification or therapeutic intervention.
Subject of Research: Genetic and molecular mechanisms linking Sjögren’s syndrome to B-cell lymphoma development
Article Title: CD74 links MHC class II risk to tumor immune microenvironment remodeling across the Sjögren-to-lymphoma axis
Article References: Liu, S., Li, M., Wang, Y., Xia, X., Wang, P., Ni, Z., Li, Q., Teng, Q., Han, W., Liu, J., Wang, X., Yu, S., Zhang, H., Meng, X., Zhong, F., & Wang, H. (2027). CD74 links MHC class II risk to tumor immune microenvironment remodeling across the Sjögren-to-lymphoma axis. Translational Oncology, 75, Article 103103. https://doi.org/10.1016/j.tranon.2026.103103
Image Credits: AI Generated
DOI: 10.1016/j.tranon.2026.103103
Keywords: Sjögren’s syndrome, non-Hodgkin lymphoma, CD74, major histocompatibility complex, 8.1 ancestral haplotype, Mendelian randomization, marginal-zone lymphoma, diffuse large B-cell lymphoma, macrophage migration inhibitory factor, single-cell RNA sequencing, salivary gland, HLA fine-mapping, AKT signaling, NF-kappaB pathway, chronic lymphocytic leukemia, Raji B cells, colocalization analysis

